Vanguard Group
PDSB icon

Vanguard Group’s PDS Biotechnology PDSB Stock Holding History

Vanguard Group’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$1.5M Buy
1,950,946
+49,505
+3% +$44.7K ﹤0.01% 3650
2025
Q3 		$1.92M Sell
1,901,441
-49,902
-3% -$58.7K ﹤0.01% 3592
2025
Q2 		$2.6M Buy
1,951,343
+441,122
+29% +$599K ﹤0.01% 3446
2025
Q1 		$1.8M Buy
1,510,221
+4,409
+0.3% +$6.27K ﹤0.01% 3522
2024
Q4 		$2.45M Sell
1,505,812
-15,731
-1% -$41.6K ﹤0.01% 3498
2024
Q3 		$5.81M Buy
1,521,543
+112,704
+8% +$376K ﹤0.01% 3212
2024
Q2 		$4.13M Sell
1,408,839
-178,967
-11% -$573K ﹤0.01% 3334
2024
Q1 		$6.29M Buy
1,587,806
+82,135
+5% +$423K ﹤0.01% 3202
2023
Q4 		$7.48M Sell
1,505,671
-2,020
-0.1% -$10K ﹤0.01% 3110
2023
Q3 		$7.61M Sell
1,507,691
-117,456
-7% -$643K ﹤0.01% 3052
2023
Q2 		$8.17M Buy
1,625,147
+326,672
+25% +$2.14M ﹤0.01% 3064
2023
Q1 		$7.99M Buy
1,298,475
+136,950
+12% +$1.12M ﹤0.01% 3065
2022
Q4 		$15.3M Buy
1,161,525
+13,447
+1% +$94.9K ﹤0.01% 2755
2022
Q3 		$3.41M Buy
1,148,078
+54,193
+5% +$230K ﹤0.01% 3518
2022
Q2 		$3.99M Hold
1,093,885
– – ﹤0.01% 3494
2022
Q1 		$6.77M Buy
1,093,885
+79,025
+8% +$491K ﹤0.01% 3365
2021
Q4 		$8.22M Buy
1,014,860
+37,158
+4% +$400K ﹤0.01% 3336
2021
Q3 		$14.6M Buy
977,702
+14,200
+1% +$177K ﹤0.01% 3038
2021
Q2 		$12.1M Buy
963,502
+102,512
+12% +$800K ﹤0.01% 3113
2021
Q1 		$3.92M Buy
860,990
+146,953
+21% +$591K ﹤0.01% 3654
2020
Q4 		$1.53M Buy
714,037
+130,211
+22% +$285K ﹤0.01% 3722
2020
Q3 		$1.36M Buy
583,826
+569,077
+3,858% +$1.6M ﹤0.01% 3591
2020
Q2 		$30K Sell
14,749
-20,105
-58% -$22.4K ﹤0.01% 4048
2020
Q1 		$25K Sell
34,854
-1,352
-4% -$2.34K ﹤0.01% 4037
2019
Q4 		$96K Sell
36,206
-1,048
-3% -$2.99K ﹤0.01% 4010
2019
Q3 		$124K Buy
37,254
+15,268
+69% +$88.8K ﹤0.01% 4014
2019
Q2 		$132K Buy
21,986
+4,814
+28% +$31.5K ﹤0.01% 4026
2019
Q1 		$127K Sell
17,172
-284
-2% -$2.37K ﹤0.01% 3987
2018
Q4 		$112K Sell
17,456
-25,602
-59% -$339K ﹤0.01% 3987
2018
Q3 		$706K Buy
43,058
+135
+0.3% +$2.43K ﹤0.01% 3792
2018
Q2 		$884K Sell
42,923
-104
-0.2% -$2.17K ﹤0.01% 3721
2018
Q1 		$1.02M Buy
43,027
+66
+0.2% +$17.8K ﹤0.01% 3645
2017
Q4 		$8.05M Buy
42,961
+3,338
+8% +$672K ﹤0.01% 2921
2017
Q3 		$8.5M Buy
39,623
+5,570
+16% +$1.15M ﹤0.01% 2889
2017
Q2 		$6.99M Sell
34,053
-947
-3% -$187K ﹤0.01% 2945
2017
Q1 		$6.38M Buy
35,000
+998
+3% +$198K ﹤0.01% 2959
2016
Q4 		$8.5M Buy
34,002
+580
+2% +$132K ﹤0.01% 2820
2016
Q3 		$6.96M Buy
33,422
+10,184
+44% +$2.02M ﹤0.01% 2846
2016
Q2 		$4.7M Buy
23,238
+12,407
+115% +$2.19M ﹤0.01% 3018
2016
Q1 		$1.98M Buy
10,831
+3,059
+39% +$547K ﹤0.01% 3387
2015
Q4 		$1.94M Buy
+7,772
New +$2.51M ﹤0.01% 3405

Other funds holding PDSB

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Vanguard Group's PDSB Position: Q4 2025 in Review

Vanguard Group increased its PDS Biotechnology (PDSB) stake by 2.6% in Q4 2025, buying an estimated $44.7K and bringing the position to 1,950,946 shares worth $1.5M. The position accounts for ﹤0.01% of the portfolio, ranked #3650.

Vanguard Group first reported a position in PDSB in Q4 2015 and has held it in 41 quarters since. The position peaked at $15.3M in Q4 2022. 44 funds tracked by Wall St. Rank hold PDSB as of Q4 2025.

  • Vanguard Group held 1,950,946 shares of PDS Biotechnology worth $1.5M as of Q4 2025.
  • Vanguard Group bought 49,505 PDS Biotechnology shares in Q4 2025, an estimated $44.7K.
  • PDS Biotechnology made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3650 holding.
  • Vanguard Group first reported a position in PDS Biotechnology in Q4 2015 and has held it in 41 quarters since.
  • Vanguard Group's PDS Biotechnology position peaked at $15.3M in Q4 2022.
  • 44 funds tracked by Wall St. Rank held PDS Biotechnology as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.